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ABSTRACT 
The  aim  of  work  is  to  characterization  and  evaluation  of  fast 
dissolving  tablet  of  Granisetron  hydrochloride  using  three 
superdisintegrants like crosscarmellose sodium, crosspovidone and 
sodium starch glycolate. FTIR studies revealed that there was no 
physico-chemical  interaction  between  granisetron  hydrochloride 
and other excipients. The tablets were prepared by dry granulation 
method and all had the same amount of ingredients except, the 
superdisintegrant  level.  The  prepared  batches  of  tablets  were 
evaluated for uniformity of weight, thickness, hardness, friability, 
disintegration time and in-vitro dissolution study. Tablet containing 
crosspovidone  showed  excellent  disintegration  time  and  drug 
release as compared to other formulations.  
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INTRODUCTION:  The  tablet  is  the  most  widely  used 
dosage form  because of its convenience  in terms of 
self-  administration,  compactness,  and  ease  in 
manufacturing.  For  the  past  one  decade,  there  has 
been an enhanced demand for more patient- friendly 
and compliant dosage forms. As a result, the demand 
for developing new technologies has been increasing 
annually. Since the development cost of a new drug 
molecule is very high, efforts are now being made by 
pharmaceutical  companies  to  focus  on  the 
development  of  new  drug  dosage  forms  for  existing 
drugs with improved safety and efficacy together with 
reduced dosing frequency, and the production of more 
cost- effective dosage forms 
1.  
Many patients find it difficult to swallow tablets and 
hard  gelatin  capsules  and  thus  do  not  comply  with 
prescription.  This  results  in  high  incidence  of 
noncompliance and ineffective therapy 
2. The proper 
choice  of  superdisintegrant  and  its  consistency  of 
performance  are  of  critical  importance  to  the 
formulation development of fast dispersible tablets 
3. 
The objective of the present study is to develop fast 
dispersible tablets of Granisetron Hydrochloride and to 
study  the  effect  of  functionality  differences  of 
superdisintegrants on the tablet properties as well as 
to  improve  the  patient  compliance  without 
compromising the therapeutic efficacy.  
Granisetron  hydrochloride  is  chemically  endo-1-
methyl- N- (9- methyl- 9- azabicyclo [3.3.1] non- 3- yl) -
H- indazole- 3- carboxamide hydrochloride, a selective 
5-HT3 receptor antagonist, which may have beneficial 
therapeutic effects in the treatment of vomiting and 
nausea  resulting  from  cancer  therapy 
4-6.  It  has  an 
improved side effect and tolerability profile, a lower 
risk of drug interactions and a longer duration of action 
than  other  5-HT3  receptor  antagonists.  It  is  also  an 
effective and well-tolerated agent in the management 
of  chemotherapy-induced,  radiotherapy-induced  and 
post-operative  nausea  and  vomiting  in  adults  and 
children 
7, 8. Its main effect is to reduce the activity of 
the vagus nerve, which is a nerve that activates the 
vomiting center in the medulla oblongata. Granisetron 
hydrochloride  undergoes  extensive  hepatic  first  pass 
metabolism with a Bioavailability of 60%. The terminal 
elimination  half-life  is  3  to  14  hours  after  oral 
administration.  Granisetron  hydrochloride  is  about 
65% bound to plasma proteins 
9. 
In the present study, an attempt was made to develop 
fast  dispersible  tablets  of  Granisetron  Hydrochloride 
and to improve its bioavailability. 
MATERIALS  AND  METHODS:  Granisetron 
hydrochloride  was  a  gift  from  Natco  Pharma  Ltd. 
(Hyderabad, India). Crosscarmellose sodium used was 
procured  from  Loba  Chemicals,  Mumbai. 
Crosspovidone and Sodium starch glycolate used were 
procured  from  Merck  Limited,  Mumbai.  Dibasic 
calcium  phosphate  used  was  procured  from  Vikas 
Pharma,  Mumbai.  All  other  reagents  and  chemicals 
used were of analytical grade. 
Preparation  of  fast  disintegrating  tablets  of 
Granisetron hydrochloride: Fast disintegrating tablets 
containing 2.4 mg of Granisetron hydrochloride were 
prepared by dry granulation method. Amount of each 
ingredient (mg) was added according to the  table 1. 
Required  quantities  of  Granisetron  hydrochloride, 
mannitol and dibasic calcium phosphate were weighed 
and  mixed  in  geometric  progression.  This  blend  was 
then forced into 12 mm die tablet press to form slugs, 
having  hardness  of  about  4.0  to  4.5  kg/cm2.  These 
slugs  were  then  milled  and  screened  through  22/44 
mesh.  
Granules retained on 44 mesh were assayed for drug 
content  and  an  amount  equivalent  to  2.4  mg  of 
Granisetron hydrochloride for one tablet was weighed 
and blended with superdisintegrants and magnesium 
stearate  as  per  the  table  1.  Superdisintegrants  and 
magnesium stearate were passed through being added 
during the lubrication step. Lubrication was done for 
three  minutes  in  a  plastic  container.  Lubricated 
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TABLE 1: FORMULATION OF GRANISETRON HYDROCHLORIDE FDT 
Formulation Code 
Granulation step (mg/tablet)      Lubrication step (mg/tablet)               
Total weight (mg) 
GHCl*  DCP*     Mannitol  CCS*  CP*  SSG*  AS*  MS* 
DC  2.4  20  77.6  --  --  --  3  3  100 
DCS1  2.4  20  69.1  2.5  --  --  3  3  100 
DCS2  2.4  20  66.6  5  --  --  3  3  100 
DCS3  2.4  20  64.1  7.5  --  --  3  3  100 
DCS4  2.4  20  61.6  10    --  3  3  100 
DCP1  2.4  20  69.1  --  2.5  --  3  3  100 
DCP2  2.4  20  66.6  --  5  --  3  3  100 
DCP3  2.4  20  64.1  --  7.5  --  3  3  100 
DCP4  2.4  20  61.6  --  10    3  3  100 
DSG1  2.4  20  69.1  --  --  2.5  3  3  100 
DSG2  2.4  20  66.6  --  --  5  3  3  100 
DSG3  2.4  20  64.1  --  --  7.5  3  3  100 
DSG4  2.4  20  61.6  --  --  10  3  3  100 
*GHCl stands for Granisetron hydrochloride; *DCP stands for dibasic calcium phosphate; *CCS stands for crosscarmellose sodium; *CP stands for 
crosspovidone; *AS stands for Aspartame; *SSG stands for sodium starch glycolate; * MG stands for Magnesium stearate 
The  granules  were  evaluated  for  various  parameters 
like  bulk  density,  tapped  density,  angle  of  repose, 
compressibility  index  and  Hausner’s  ratio.  After 
evaluation of granules, the tablets were compressed 
with  a  ten-station  rotary  punch-tableting  machine 
(Rimek Mini Press-1) using 6 mm flat punches set. 
Evaluation of powder blends 
10-13: 
Bulk  density:  Apparent  bulk  density  (ρb)  was 
determined by placing presieved drug excipients blend 
into a graduated cylinder and measuring the volume 
(Vb) and weight (M) “as it is”.  
ρb = M/Vb 
Tapped density: The measuring cylinder containing a 
known mass of blend was tapped for a fixed number of 
taps.  The  minimum  volume  (Vt)  occupied  in  the 
cylinder  and  the  weight  (M)  of  the  blend  was 
measured.  The  tapped  density  (ρt)  was  calculated 
using following formula. 
ρt = M/ Vt 
Angle of repose: Angle of repose (θ) was determined 
using funnel method. The blend was poured through a 
funnel that can be raised vertically until a maximum 
cone height (h) was obtained. The radius of the heap 
(r) was measured and angle of repose was calculated.  
θ = tan
-1 h/r 
Compressibility  index:  The  simplest  way  of 
measurement  of  free  flow  property  of  powder  is 
compressibility, an indication of the ease with which a 
material  can  be  induced  to  flow  is  given  by  % 
compressibility that is calculated as follows: 
C = (ρt – ρb) / ρt x 100 
ρt - Tapped density, ρb - Untapped bulk density 
Hausner’s ratio: Hausner’s ratio is an index of ease of 
powder flow; it is calculated by following formula. 
Hausner’s ratio = ρt\ ρb 
ρt - Tapped density, ρb -Untapped bulk density 
Evaluation  of  Granisetron  Hydrochloride  fast 
disintegrating tablets 
14-16: 
Weight variation test: Weight variation test was done 
by weighing 20 tablets individually, by using Sartorious 
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weight and comparing the individual tablet weight to 
the average weight. 
Tablet  thickness:  The  thickness  was  measured  by 
placing  tablet  between  two  arms  of  the  Vernier 
calipers. 5 tablets were taken and their thickness was 
measured.
  
Tablet  hardness:  The  tablet  hardness,  which  is  the 
force  required  to  break  a  tablet  in  a  diametric 
compression  force.  The  hardness  tester  used  in  the 
study  was  Monsanto  hardness  tester,  which  applies 
force to the tablet diametrically with the help  of an 
inbuilt spring. 
Tablet  friability:  The  friability  of  the  tablets  was 
measured in a Roche Friabilator (Camp-bell Electronics, 
Mumbai). Tablets of a known weight (Wo) or a sample 
of 20 tablets are dedusted in a drum for a fixed time 
(100 revolutions) and weighed (W) again. Percentage 
friability  was  calculated  from  the  loss  in  weight  as 
given in equation as below. The weight loss should not 
be  more  than  1  %.  Determination  was  made  in 
triplicate. 
% Friability = 100 (Wo -W) / Wo 
In-vitro disintegration time:  The disintegration time of 
tablets  was  determined  at  37±1
oC  according  to  the 
method described in the British Pharmacopoeia, 1998. 
In-vitro  dissolution  study:  The  release  rate  of 
Granisetron hydrochloride from fast dispersible tablets 
was  determined  using  United  State  Pharmacopoeia 
(USP)  XXIV  dissolution  testing  apparatus  II  (paddle 
method). The dissolution test was performed using 900 
ml  of  phosphate  buffer  pH  6.8  as  a  dissolution 
medium, at 37±0.5
oC and 50 rpm. A sample (5 ml) of 
the  solution  was  withdrawn  from  the  dissolution 
apparatus  at  different  time  interval  (minutes).  The 
samples  were  filtered  through  a  0.45  membrane 
filter. Absorbance of these solutions was measured at 
302  nm  using  a  PG  instrument  T80  model  UV/VIS 
spectrophotometer.  Cumulative  percentage  of  drug 
release  was  calculated  using  an  equation  obtained 
from a standard curve. 
Drug content estimation: Powder equivalent to 2.24 
mg  of  Granisetron  hydrochloride  was  dissolved  in 
phosphate  buffer  pH  6.8.  Sufficient  dilutions  were 
made to obtain 10 mcg/ml solution. Absorbance of the 
resulting solution was measured at 302 nm using a PG 
instrument  T80  model  UV/VIS  spectrophotometer. 
From the absorbance values, amount of drug present 
in  the  given  tablet  was  calculated.  Procedure  was 
repeated  by  using  four  more  tablets  from  the  same 
formulation and the average value of all five tablets 
was calculated. 
FTIR  Spectroscopy:  The  Fourier-transform  infrared 
spectra  of  Granisetron  hydrochloride  and  mixture 
granisetron hydrochloride with other excipients were 
obtained  by  using  FTIR  spectroscopy-  5300  (JASCO 
Japan). Samples were prepared by KBr pressed pellet 
technique. The scanning range was 400-4600 cm
-1 and 
the resolution was 4 cm
-1. The spectra are shown in 
Fig. 1 to 5. 
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FIG. 2: FTIR SPECTRUM OF GRANISETRON HYDROCHLORIDE- DCP 
 
FIG. 3: FTIR SPECTRUM OF GRANISETRON HYDROCHLORIDE- CROSSCARMELLOSE SODIUM 
 
FIG. 4: FTIR SPECTRUM OF GRANISETRON HYDROCHLORIDE- CROSSPOVIDONE 
 
FIG.5: FTIR SPECTRUM OF GRANISETRON HYDROCHLORIDE- SODIUM STARCH GLYCOLATE
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RESULTS AND DISCUSSION: FTIR studies revealed that 
there  was  no  physico-chemical  interaction  between 
Granisetron hydrochloride and other excipients (Fig. 1 
to 5).  For each designed formulation, blend of drug 
and  excipients  was  prepared  and  evaluated  for 
micromeritics properties shown in table 2. Bulk density 
was  found  to  be  between  0.32±0.007  to 
0.38±0.001gm/ml  and  tapped  density  between 
0.35±0.002 to 0.43±0.001 gm/ml for all formulations. 
Hausner’s  ratio  was  found  below  1.2  and  Carr’s 
compressibility  index  between  10-  16  for  all 
formulations.  The  angle  of  repose  is  known  to  be  a 
measure of flowability and the angle of repose of all 
formulations  was  found  between  20.14±0.63  to 
25.31±1.07  it  indicate  good  flow  properties  of 
granules.
 
All batches of the tablets were evaluated for various 
physical  parameters  shown  in  table  3.  The  weight 
variation  of  all  the  tablets  was  within  the  ranges  of 
097±0.18 to 104±0.56 mg. The hardness of the tablets 
was within the range of 2.00.12 to 2.80.15 kg/cm2. 
The  friability  of  all  tablets  below  1%  and  the 
disintegration time of different formulations are shown 
in figure 6. All the formulations had disintegration time 
was  found  between  421.24  to  701.10  seconds 
(crosspovidone>  crosscarmellose  sodium>  sodium 
starch glycolate). The influences of superdisintegrants 
on the dissolution of granisetron hydrochloride from 
the tablets are shown in Fig. 7 to 9. The drug release 
increased  with  increase  in  the  level  of 
superdisintegrants. Out of thirteen formulations DCP4 
formulation  shows  best  drug  release  99.90%  in  10 
minutes.  
TABLE 2: PRE COMPRESSION PARAMETERS DATA FOR GRANISETRON HYDROCHLORIDE POWDER BLEND 
Formulation Code 
Parameters 
Bulk density* (gm/ml)  Tapped density*   (gm/ml)  Hausner’s ratio*  Carr’s index* (%)  Angle of repose* (θ) 
DC  0.380.001  0.420.003  1.08±0.03  7.42±0.56  23.16±0.75 
DCS1  0.340.006  0.390.002  1.13±0.01  11.92±1.22  22.47±0.13 
DCS2  0.360.003  0.390.003  1.10±0.03  9.33±1.54  24.38±1.10 
DCS3  0.320.007  0.400.001  1.10±0.02  9.84±1.09  21.45±1.13 
DCS4  0.360.004  0.360.004  1.05±0.03  5.34±1.47  25.11±0.27 
DCP1  0.330.003  0.360.001  1.08±0.04  8.10±1.26  23.41±1.32 
DCP2  0.340.004  0.370.001  1.08±0.01  8.01±2.05  21.26±1.27 
DCP3  0.360.004  0.390.002  1.06±0.01  6.50±1.04  23.17±1.65 
DCP4  0.330.001  0.480.001  1.15±0.03  13.77±0.86  24.10±1.13 
DSG1  0.370.007  0.410.002  1.11±0.02  10.15±0.49  21.10±0.81 
DSG2  0.320.007  0.350.002  1.10±0.03  9.10±1.39  20.14±0.63 
DSG3  0.340.004  0.370.002  1.08±0.02  7.94±1.33  24.19±1.07 
DSG4  0.360.004  0.390.002  1.07±0.03  6.63±1.52  23.18±1.23 
* Average of three determinations 
TABLE 3: EVALUATION OF GRANISETRON HYDROCHLORIDE FDT 
Formulation Code 
Formulation parameters 
Weight 
Variation* 
Thickness* 
(mm) 
Hardness* 
(kg/cm
2) 
Friability 
(%) 
Disintegration       
time*  (sec) 
% Drug release 
(10 min) 
DC  102±1.45  2.98 0.41  2.1  0.42  0.81  2651.22  12.31 
DCS1  103±1.62  3.05 0.17  2.3  0.15  0.69  581.16  88.26 
DCS2  098±1.73  3.00 0.45  2.3  0.20  0.75  492.35  96.34 
DCS3  104±1.69  3.01 0.26  2.5  0.05  0.59  321.57  98.00 
DCS4  101±0.96  3.20 0.18  2.2  0.10  0.58  301.11  98.50 
DCP1  100±1.85  3.17 0.09  2.8  0.15  0.73  610.56  81.56 
DCP2  097±0.18  3.11 0.01  2.1  0.24  0.77  521.28  93.57 
DCP3  099±1.50  3.03 0.23  2.1  0.10  0.60  541.50  97.02                                                        International Journal of Pharmaceutical Sciences and Research                        ISSN: 0975-8232 
                                                                         Available online on www.ijpsr.com                                                                      1286 
 
DCP4  103±1.21  3.16 0.20  2.3  0.21  0.58  430.38  99.90 
DSG1  097±1.93  3.10 0.11  2.2  0.15  0.66  711.10  72.12 
DSG2  098±0.65  3.11 0.13  2.3  0.10  0.62  590.21  87.19 
DSG3  100±1.97  3.19 0.09  2.2  0.18  0.58  481.29  89.99 
DSG4  104±0.56  2.97 0.14  2.0  0.12  0.56  421.24  96.38 
* Average of three determinations 
 
 
FIG.  6:  DISINTEGRATION  TIME  OF  VARIOUS  GRANISETRON 
HYDROCHLORIDE FDT FORMULATIONS 
 
FIG.  7:  DRUG  RELEASE  PROFILE  OF  FORMULATIONS  CONTAINING 
CROSSCARMELLOSE SODIUM 
 
FIG.  8:  DRUG  RELEASE  PROFILE  OF  FORMULATIONS  CONTAINING 
CROSSPOVIDONE 
 
FIG.9:  DRUG  RELEASE  PROFILE  OF  FORMULATIONS  CONTAINING 
SODIUM STARCH GLYCOLATE 
CONCLUSION: It can be concluded that disintegration 
time and dissolution rate of granisetron hydrochloride 
can be enhanced to a great extent by dry granulation 
technique  with  the  addition  of  superdisintegrants. 
Further  investigations  are  needed  to  confirm  the  in-
vivo efficiency. 
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